| human | Q5 |
| P9984 | CANTIC ID | 981058517694006706 |
| P227 | GND ID | 121608174 |
| P269 | IdRef ID | 067001262 |
| P244 | Library of Congress authority ID | n93802888 |
| P8189 | National Library of Israel J9U ID | 987007350440605171 |
| P1006 | Nationale Thesaurus voor Auteursnamen ID | 227288734 |
| P11686 | University of Barcelona authority ID | 981058517694006706 |
| P1580 | University of Barcelona authority ID (former scheme) | a1037816 |
| P214 | VIAF ID | 19856822 |
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q95359426 | Q95359426 |
| Q38008403 | 'Overlap' syndromes |
| Q91255436 | 'Seronegative antiphospholipid syndrome': an update |
| Q35086343 | 25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort |
| Q95324153 | A Comparison of 2019 EULAR/ACR SLE Classification Criteria with Two Sets of Earlier SLE Classification Criteria |
| Q38409092 | A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach |
| Q35177106 | A Study of 100 High Risk Lupus Pregnancies |
| Q40688648 | A candidate gene analysis of three related photosensitivity disorders: cutaneous lupus erythematosus, polymorphic light eruption and actinic prurigo |
| Q33330540 | A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies |
| Q71711323 | A need for standardization of the anti-endothelial-cell antibody test |
| Q87384439 | A new dawn of anticoagulation for patients with antiphospholipid syndrome? |
| Q74395434 | A normal ECG at birth does not exclude significant congenital cardiac conduction disease associated with maternal anti-Ro antibodies |
| Q33496452 | A study of sixty pregnancies in patients with the antiphospholipid syndrome. |
| Q37020336 | A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies |
| Q33500783 | A young woman with SLE: diagnostic and therapeutic challenges |
| Q37232102 | ACP Broadsheet no 136: February 1993. Detection and importance of anticardiolipin antibodies |
| Q73608534 | Absence of conduction defects in the electrocardiograms [correction of echocardiograms] of mothers with children with congenital complete heart block |
| Q96221671 | Accrual of atherosclerotic vascular events in a multicentre inception SLE cohort |
| Q31145074 | Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort |
| Q69169630 | Acute cerebral organic syndrome, systemic lupus erythematosus and antiphospholipid antibodies |
| Q37326295 | Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature |
| Q38167486 | Adult haemophagocytic syndrome |
| Q46740396 | Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment |
| Q33502464 | Advances in antiphospholipid (Hughes') syndrome |
| Q36951011 | Advances in lupus and Sjögren's syndrome: a tribute to Josep Font |
| Q52545176 | Allergic disorders in systemic lupus erythematosus. |
| Q72687596 | Allergic disorders in systemic vasculitis: a case-controlled study |
| Q45345442 | American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort |
| Q60699893 | An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA |
| Q59297874 | An empirical methodology for prediction of shape and flow rate of a free-falling non-submerged liquid and casting iron stream |
| Q74024011 | An evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of arterial thrombosis in patients with the antiphospholipid syndrome |
| Q60311597 | Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus |
| Q37633408 | Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus |
| Q49171522 | Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus |
| Q35555256 | Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus |
| Q34717540 | Anti-C1q antibodies in systemic lupus erythematosus |
| Q47833355 | Anti-PL4 antibody in SLE. |
| Q70691249 | Anti-Ro and lymphopenia in SLE |
| Q35953541 | Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome |
| Q35552732 | Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis |
| Q67961140 | Anti-endothelial cell antibodies in systemic lupus erythematosus: association with vascular and renal lesions |
| Q77291193 | Anti-endothelial cell antibodies in systemic vasculitis and systemic lupus erythematosus (SLE): effects of heat inactivation on binding and specificity |
| Q72220659 | Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Behçet's disease |
| Q40984244 | Anti-endothelial cell antibodies: only for scientists or for clinicians too? |
| Q28218219 | Anti-inflammatory and immunosuppressive drugs and reproduction |
| Q67503399 | Anti-myeloperoxidase autoantibodies in patients with necrotizing glomerular and alveolar capillaritis |
| Q38026345 | Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome |
| Q86613937 | Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review |
| Q28182136 | Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndrome |
| Q57602185 | Antibodies against endothelial cells in patients with multiple sclerosis |
| Q44557656 | Antibodies against platelet-activating factor in patients with antiphospholipid antibodies |
| Q79092333 | Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance |
| Q54511727 | Antibodies to beta2-glycoprotein I: a potential marker for clinical features of antiphospholipid antibody syndrome in patients with systemic lupus erythematosus. |
| Q43090289 | Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with 'seronegative' antiphospholipid syndrome |
| Q35178701 | Antibodies to endothelial cells in dermatomyositis: association with interstitial lung disease |
| Q70781062 | Antibodies to endothelial cells in patients with Behçet's disease |
| Q41126709 | Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. |
| Q67930596 | Antibodies to endothelial cells in systemic lupus erythematosus: a potential marker for nephritis and vasculitis |
| Q39273389 | Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis |
| Q71198243 | Anticardiolipin antibodies and cardiovascular disease |
| Q33360177 | Anticardiolipin antibodies in a patient with Crohn's disease and thrombosis |
| Q72631049 | Anticardiolipin antibodies in isolated retinal vasculitis |
| Q33388232 | Anticardiolipin antibodies in patients from Malaysia with systemic lupus erythematosus |
| Q35719544 | Anticardiolipin antibody |
| Q80939143 | Anticardiolipin test and the antiphospholipid (Hughes) syndrome: 20 years and counting! |
| Q67886354 | Antiendothelial Cell Antibodies in Patients with the Antiphospholipid Syndrome |
| Q41519646 | Antiendothelial cell antibodies (AECA) in systemic lupus erythematosus (SLE) |
| Q73385994 | Antiendothelial cell antibodies in inflammatory myopathies: distribution among clinical and serologic groups and association with interstitial lung disease |
| Q33228254 | Antiferritin antibodies discovered by phage display expression cloning are associated with radiographic damage in rheumatoid arthritis |
| Q90465816 | Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort |
| Q87345720 | Antiphosphatidylserine/prothrombin antibodies in systemic lupus erythematosus |
| Q42781470 | Antiphospholipid (Hughes') syndrome |
| Q35934717 | Antiphospholipid (Hughes) syndrome |
| Q33893371 | Antiphospholipid (Hughes) syndrome in systemic lupus erythematosus |
| Q36222874 | Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. |
| Q33564539 | Antiphospholipid antibodies and HLA associations in primary Sjögren's syndrome |
| Q40921565 | Antiphospholipid antibodies and antiphospholipid syndrome. |
| Q47371855 | Antiphospholipid antibodies and risk for recurrent vascular events |
| Q67834951 | Antiphospholipid antibodies and shrinking lungs in SLE |
| Q34108976 | Antiphospholipid antibodies and the endothelium |
| Q69920926 | Antiphospholipid antibodies and thrombosis |
| Q70503224 | Antiphospholipid antibodies and valve disease in patients with systemic lupus erythematosus |
| Q67874633 | Antiphospholipid antibodies cross-reacting with erythrocyte membranes. A case report |
| Q28192812 | Antiphospholipid antibodies do not a syndrome make |
| Q82132738 | Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK- |
| Q69392979 | Antiphospholipid antibodies in a Brazilian population with systemic lupus erythematosus |
| Q48709466 | Antiphospholipid antibodies in cerebral ischemia |
| Q33567640 | Antiphospholipid antibodies in homozygous sickle cell disease |
| Q74193573 | Antiphospholipid antibodies in leprotic patients: a correlation with disease manifestations |
| Q45309660 | Antiphospholipid antibodies in neurology. Reality or fiction? |
| Q43049326 | Antiphospholipid antibodies in patients with scleroderma: prevalence and clinical significance |
| Q72323545 | Antiphospholipid antibodies in sickle cell disease |
| Q35553271 | Antiphospholipid antibodies, systemic lupus erythematosus, and non-traumatic metatarsal fractures |
| Q69594854 | Antiphospholipid antibodies, valvular heart disease and systemic lupus erythematosus |
| Q72731758 | Antiphospholipid antibodies--middle aged but robust |
| Q40559210 | Antiphospholipid antibodies. A marker for thrombosis and recurrent abortion |
| Q42778868 | Antiphospholipid antibodies: which and when? |
| Q72417034 | Antiphospholipid antibody syndrome |
| Q35554909 | Antiphospholipid antibody tests: spreading the net |
| Q55891386 | Antiphospholipid syndrome |
| Q72611389 | Antiphospholipid syndrome |
| Q63581739 | Antiphospholipid syndrome |
| Q38841201 | Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria? |
| Q91909168 | Antiphospholipid syndrome and infertility |
| Q73505498 | Antiphospholipid syndrome and renal artery stenosis |
| Q72011165 | Antiphospholipid syndrome and the idiotypic network |
| Q36502421 | Antiphospholipid syndrome and the kidneys |
| Q53349053 | Antiphospholipid syndrome in SLE. |
| Q80327853 | Antiphospholipid syndrome in pregnancy |
| Q73737678 | Antiphospholipid syndrome: a consensus for treatment? |
| Q38410376 | Antiphospholipid syndrome: an update |
| Q33341941 | Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients |
| Q84601614 | Antiphospholipid syndrome: coming of age |
| Q33561642 | Antiphospholipid syndrome: linking many specialties |
| Q35150503 | Antiphospholipid syndrome: obstetric diagnosis, management, and controversies |
| Q33546571 | Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future |
| Q33327909 | Antiphospholipid, anti-beta 2-glycoprotein-I and anti-oxidized-low-density-lipoprotein antibodies in antiphospholipid syndrome |
| Q37955583 | Antiphospohlipid syndrome in obstetrics |
| Q81402660 | Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus |
| Q40536903 | Appearance of systemic lupus erythematosus after thymectomy: four case reports and review of the literature |
| Q74552370 | Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1 |
| Q77291742 | Arterial disease in lupus and secondary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein |
| Q50020978 | Arterial stenosis in antiphospholipid syndrome: Update on the unrevealed mechanisms of an endothelial disease |
| Q28188267 | Aspirin to treat obstetric manifestations of the antiphospholipid syndrome |
| Q73198900 | Assessing disease activity in SLE patients during pregnancy |
| Q48144813 | Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. |
| Q35553733 | Association of HLA-DM polymorphism with the production of antiphospholipid antibodies |
| Q41837002 | Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus |
| Q73574482 | Association of antiphosphatidylserine/prothrombin autoantibodies with HLA class II genes |
| Q71775354 | Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus |
| Q33410947 | Association of thrombotic microangiopathy and intimal hyperplasia with bleeding post-renal biopsy in antiphospholipid antibody-positive patients |
| Q35085895 | Atherogenic autoantigen: oxidized LDL complexes with beta2-glycoprotein I. |
| Q77344825 | Atheroma: links with antiphospholipid antibodies, Hughes syndrome and lupus |
| Q34243799 | Atherosclerosis and autoimmunity |
| Q61895088 | Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment |
| Q34338929 | Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus |
| Q47586174 | Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death |
| Q72786337 | Autoantibodies against endothelial cells, extracellular matrix, and human collagen type IV in patients with systemic vasculitis |
| Q73313533 | Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome |
| Q73895637 | Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome |
| Q36307423 | Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study |
| Q36332517 | Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus |
| Q70791702 | Autoantibodies in systemic lupus erythematosus and urticarial vasculitis |
| Q38222127 | Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review |
| Q38015047 | Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome |
| Q39716593 | Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome |
| Q47957293 | Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus |
| Q56907567 | Autoimmune Diseases Induced by TNF-Targeted Therapies |
| Q38695221 | Autoimmune congenital heart block: complex and unusual situations |
| Q37333105 | Autoimmune diseases induced by TNF-targeted therapies |
| Q37620986 | Autoimmune diseases induced by biological agents: a double-edged sword? |
| Q39171818 | Autologous hematopoietic stem cell transplantation in Systemic Lupus Erythematosus and antiphospholipid syndrome: A systematic review |
| Q33494659 | Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus |
| Q33407206 | B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases |
| Q37586344 | B-cell-depleting therapy in systemic lupus erythematosus |
| Q60699961 | BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus |
| Q80370140 | BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000 |
| Q40838691 | BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids |
| Q40838685 | BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice |
| Q77549919 | Beta2-glycoprotein I as a 'cofactor' for anti-phospholipid reactivity with endothelial cells |
| Q47901692 | Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system |
| Q38289398 | Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies |
| Q33342481 | Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. |
| Q37137162 | British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus |
| Q70691221 | Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity |
| Q33835528 | Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature |
| Q98566780 | Cancer risk in a large inception SLE cohort: Effects of demographics, smoking, and medications |
| Q35189299 | Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report |
| Q83667355 | Cardiac valve replacement in patients with antiphospholipid syndrome |
| Q36811755 | Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort |
| Q22255576 | Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines |
| Q38040219 | Central nervous system involvement in systemic lupus erythematosus: Overview on classification criteria |
| Q35069507 | Central nervous system involvement in the antiphospholipid (Hughes) syndrome |
| Q74793612 | Cerebral embolism complicating Libman-Sacks endocarditis--full recovery using recombinant tissue plasminogen activator |
| Q47556201 | Cerebrovascular Events in Systemic Lupus Erythematosus |
| Q41238775 | Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome |
| Q48086630 | Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus |
| Q28181800 | Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment |
| Q62395238 | Characterization of the Endothelial Surface Proteins Recognized by Anti-Endothelial Antibodies in Primary and Secondary Autoimmune Vasculitis |
| Q33570170 | Chorea in systemic lupus erythematosus: association with antiphospholipid antibodies |
| Q43564133 | Chromium-51 ethylenediamine tetraacetic acid glomerular filtration rate: a better predictor than glomerular filtration rate calculated by the Cockcroft-Gault formula for renal involvement in systemic lupus erythematosus patients |
| Q44300088 | Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen |
| Q95422702 | Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities |
| Q34279359 | Clinical advances of interest in the diagnosis and treatment of patients with antiphospholipid syndrome |
| Q40529762 | Clinical and therapeutic aspects of the antiphospholipid syndrome |
| Q30560952 | Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort |
| Q37356697 | Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review |
| Q37654616 | Clinical guidelines for the management of acute viral infections in patients with systemic lupus erythematosus |
| Q31122937 | Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort |
| Q37939702 | Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS'). |
| Q41253910 | Clinical significance of anti-beta 2-glycoprotein I antibodies. |
| Q67947237 | Clinical, endoscopic, immunologic, and therapeutic aspects of oropharyngeal and esophageal candidiasis in HIV-infected patients: a survey of 114 cases |
| Q46988388 | Closing the Serological Gap in the Antiphospholipid Syndrome: The Value of "Non-criteria" Antiphospholipid Antibodies |
| Q89076135 | Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply |
| Q72764443 | Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients |
| Q33584134 | Complement factor 2 deficiency: a clinical and serological family study |
| Q93110379 | Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus |
| Q59297901 | Contact problems of a trochoidal-gear pump |
| Q78589611 | Contraceptive practices in women with systemic lupus erythematosus and/or antiphospholipid syndrome: what advice should we be giving? |
| Q73029368 | Correlation between beta2-glycoprotein I valine/leucine247 polymorphism and anti-beta2-glycoprotein I antibodies in patients with primary antiphospholipid syndrome |
| Q38818425 | Current status and future prospects for the treatment of antiphospholipid syndrome |
| Q41977234 | Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus |
| Q71746942 | Detection of brain-reactive autoantibodies in the sera of patients with systemic lupus erythematosus and cerebral involvement |
| Q50118870 | Determination of autoantibodies to annexin XI in systemic autoimmune diseases |
| Q35229755 | Development and initial validation of a self-assessed lupus organ damage instrument |
| Q35642120 | Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice |
| Q71017849 | Development of systemic lupus erythematosus after chemotherapy and radiotherapy for malignant thymoma |
| Q58610580 | Development of the Asia Pacific Lupus Collaboration cohort |
| Q41238763 | Diabetic cheirarthropathy simulating sclerodermia |
| Q47998109 | Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances |
| Q36577371 | Diagnosis of antiphospholipid syndrome |
| Q82480200 | Diagnosis of antiphospholipid syndrome |
| Q54443076 | Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome. |
| Q39449741 | Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment |
| Q57650031 | Distribution of two common idiotypes of anticardiolipin antibodies in sera of patients with primary antiphospholipid syndrome, systemic lupus erythematosus and monoclonal gammopathies |
| Q77365501 | Does SLE flare during pregnancy? |
| Q38089684 | Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop? |
| Q51906668 | EASI - The European Autoimmunity Standardisation Initiative: a new initiative that can contribute to agreed diagnostic models of diagnosing autoimmune disorders throughout Europe. |
| Q68341147 | ELISA using Thrombofax is useful to verify antiphospholipid antibodies |
| Q37128198 | EULAR points to consider for conducting clinical trials in systemic lupus erythematosus |
| Q37146930 | EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints |
| Q92048496 | EULAR recommendations for the management of antiphospholipid syndrome in adults |
| Q33284736 | EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics |
| Q33731711 | EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome |
| Q67470049 | Early Doppler Studies in Lupus Pregnancy |
| Q39294990 | Echocardiography and digital subtraction angiography in detection of mycotic false aneurysm complicating coarctation of the aorta |
| Q90690732 | Economic evaluation of damage accrual in an international SLE inception cohort using a multi-state model approach |
| Q47385774 | Economic evaluation of lupus nephritis in the Systemic Lupus International Collaborating Clinics inception cohort using a multistate model approach |
| Q53827335 | Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. |
| Q73397102 | Effect of beta 2glycoprotein I and human monoclonal anticardiolipin antibody on the protein S/C4b-binding protein system |
| Q72676756 | Effects of an aromatase inhibitor on thymus and kidney and on oestrogen receptors in female MRL/MP-lpr/lpr mice |
| Q47685798 | Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes |
| Q43781981 | Effects of oestradiol and the oestrogen antagonist Ici 182,780 on the delayed type hypersensitivity (DTH) index and on serum levels of IgM and IgG in ovariectomised Balb/C and MRL/Mp-Lpr/Lpr mice, a model of systemic lupus erythematosus (SLE). |
| Q61914569 | Effects of β2-glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions |
| Q47373774 | Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome |
| Q34060110 | Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts |
| Q74151261 | Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome |
| Q36581666 | Endocrinologic manifestations of the antiphospholipid syndrome |
| Q34021310 | Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome |
| Q41084661 | Endothelial cells as a target for antiphospholipid antibodies: role of anti-beta 2 glycoprotein I antibodies. |
| Q62395215 | Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti-β2-Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β2-Glycoprotein I and Induce Endothelial Activation |
| Q82572403 | Epidemiology of systemic lupus erythematosus at the change of the millennium: lessons from the Euro-Lupus and the LUMINA projects |
| Q71704999 | Epitope specificity of monoclonal anti-beta 2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome |
| Q34283330 | Estrogen and progesterone receptors in murine models of systemic lupus erythematosus |
| Q35555112 | Ethnic and geographical variation in antiphospholipid (Hughes) syndrome |
| Q34187282 | European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies |
| Q34491073 | European Working Party on Systemic Lupus Erythematosus: a 10 year report |
| Q51935782 | European attempts to set guidelines for improving diagnostics of autoimmune rheumatic disorders. |
| Q91640246 | Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus |
| Q40475642 | Evaluation of systemic lupus erythematosus activity during pregnancy. |
| Q73291749 | Evidence for sexual dimorphism of estrogen receptors in hypothalamus and thymus of neonatal and immature Wistar rats |
| Q83389363 | Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies |
| Q46301201 | Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort |
| Q35760150 | Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus |
| Q28608340 | Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort |
| Q41936669 | Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study |
| Q59159759 | Familial clustering of polymorphic light eruption in relatives of patients with lupus erythematosus: evidence of a shared pathogenesis |
| Q33502629 | Fcgamma receptor IIA H/R131 polymorphism in patients with antiphospholipid antibodies. |
| Q33361525 | Features associated with epilepsy in the antiphospholipid syndrome |
| Q53704347 | Fibrinogen in systemic lupus erythematosus: more than an acute phase reactant? |
| Q57843653 | Fine specificity of autoantibodies to calreticulin: epitope mapping and characterization |
| Q83992557 | First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss |
| Q53163004 | Fluctuation of anti-endothelial cell antibody titers in " mixed connective tissue disease. |
| Q59297894 | Friction effects on the load capacity of a column and a hydraulic cylinder |
| Q44993606 | GAPSS: the Global Anti-Phospholipid Syndrome Score |
| Q59297897 | GEROLAB Package System: Innovative Tool to Design a Trochoidal-Gear Pump |
| Q48423132 | Gadolinium-enhanced magnetic resonance imaging of the central nervous system in systemic lupus erythematosus |
| Q45228945 | Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies |
| Q42647843 | Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus |
| Q67599278 | Genetics of antiendothelial cell antibodies in systemic lupus erythematosus: the role of HLA-DP alleles |
| Q37978291 | Glucocorticoid use and abuse in SLE. |
| Q47557472 | Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort |
| Q78637200 | Goldblatt's kidney, Hughes syndrome and hypertension |
| Q30923489 | Google-driven search for big data in autoimmune geoepidemiology: analysis of 394,827 patients with systemic autoimmune diseases |
| Q73395887 | HLA class II gene polymorphisms in antiphospholipid syndrome: haplotype analysis in 83 Caucasoid patients |
| Q68086085 | HLA-DP genotyping in patients with systemic lupus erythematosus: correlations with autoantibody subsets |
| Q43756009 | Haemophilus endocarditis |
| Q77484135 | Headache and memory loss: rapid response to heparin in the antiphospholipid syndrome |
| Q44915681 | Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study |
| Q34157396 | Heparin and osteoporosis during pregnancy: 2002 update |
| Q67911740 | High Prevalence of Significant Heart Valve Lesions in Patients with the 'Primary' Antiphospholipid Syndrome |
| Q37950724 | High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. |
| Q36888567 | How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review |
| Q31101744 | Hughes syndrome and epilepsy: when to test for antiphospholipid antibodies? |
| Q35172192 | Hughes syndrome crosses boundaries |
| Q53109757 | Hughes syndrome: 'sticky blood'. |
| Q71954239 | Hughes syndrome: antiphospholipid antibodies move closer to thrombosis in 1994 |
| Q48313140 | Human Ro60 (SSA2) genomic organization and sequence alterations, examined in cutaneous lupus erythematosus |
| Q48032183 | Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies |
| Q33579097 | Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases |
| Q46643929 | Hydroxychloroquine: the cornerstone of lupus therapy |
| Q72692336 | Hypertension and the antiphospholipid antibodies |
| Q74225484 | Hypertension as the presenting feature of the antiphospholipid syndrome |
| Q67959162 | IL-2, IL-6 and TNF levels in primary antiphospholipid syndrome |
| Q47685723 | IgG2 restriction of anti-beta2-glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome: comment on the article by Sammaritano et al. |
| Q33448386 | Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes |
| Q94550478 | Immune-related adverse events of checkpoint inhibitors |
| Q50911536 | Immunological findings in Kawasaki disease: an evaluation in a cohort of Italian children. |
| Q73402376 | Immunosuppressive therapy in lupus nephritis |
| Q35547376 | Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide |
| Q30791606 | Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort |
| Q38312771 | Impaired estrogen priming of progesterone receptors in uterus of MRL/MP-lpr/lpr mice, a model of systemic lupus erythematosus (SLE). |
| Q36477458 | Improved monitoring of clinical response in Systemic Lupus Erythematosus by longitudinal trend in soluble vascular cell adhesion molecule-1. |
| Q56907309 | Incorrect Values for Intractable and Cluster Headaches at Enrollment Shown in Figure 1 and Incorrect Prevalence of Headache at Ten Years in Text of the Article by Hanly et al (Arthritis Rheum, November 2013) |
| Q73521719 | Increase in the heart rate-corrected QT interval in children of anti-Ro-positive mothers, with a further increase in those with siblings with congenital heart block: comment on the article by Cimaz et al |
| Q44250405 | Increased cutaneous reactions to hydroxychloroquine (Plaquenil) possibly associated with formulation change: comment on the letter by Alarcón |
| Q41931544 | Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies |
| Q84658059 | Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome |
| Q41050054 | Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies |
| Q41217831 | Infective endocarditis, rheumatoid factor, and anticardiolipin antibodies |
| Q70189013 | Inhibition of chronic relapsing experimental allergic encephalomyelitis in the mouse by the alkyl-lysophospholipid ET-18-OCH3 |
| Q91454517 | Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome |
| Q37998986 | Intensity and duration of anticoagulation therapy in antiphospholipid syndrome |
| Q78472137 | Intensity and duration of oral anticoagulation in antiphospholipid antibody associated thrombosis |
| Q46470743 | Interethnic differences in the association of tumor necrosis factor promoter polymorphisms with systemic lupus erythematosus |
| Q33685960 | International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop |
| Q38152619 | International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies |
| Q86998139 | Irrational testing for antiphospholipid antibodies |
| Q38094529 | Is it time for biosimilars in autoimmune diseases? |
| Q33448758 | Is there a role for phospholipases in the anti-cardiolipin syndrome? |
| Q33369430 | Isotype profile and clinical relevance of anticardiolipin antibodies in Sjogren's syndrome |
| Q36458164 | Laboratory diagnosis and management challenges in the antiphospholipid syndrome |
| Q67483559 | Lack of Specific Binding of Anticardiolipin Antibodies to Intact Platelets |
| Q57602230 | Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus |
| Q73611473 | Lack of association between antiphospholipid antibody and WHO classification in lupus nephritis |
| Q79390809 | Lack of association of antibodies to ribosomal P proteins with lupus membranous glomerulonephritis: comment on the article by Do Nascimento et al |
| Q77134238 | Lack of cross-reaction between antibodies to beta2-glycoprotein-I and oxidized low-density lipoprotein in patients with antiphospholipid syndrome |
| Q41715475 | Late pregnancy complications in systemic lupus erythematosus and antiphospholipid syndrome. |
| Q73063639 | Lessons from the "Euro-Lupus Cohort" |
| Q43690452 | Letter to the Editor in response to the article "Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: a review of published literature and registered clinical trials." by Gleicher N, Elkayam U, A |
| Q33915460 | Lipoprotein(a) oxidation and autoantibodies: a new path in atherothrombosis |
| Q44286675 | Lipoproteins and atherosclerosis in systemic lupus erythematosus |
| Q79402374 | Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome |
| Q33367182 | Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? |
| Q28196730 | Longitudinal analysis of serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 in antiphospholipid syndrome and in healthy pregnancy |
| Q28194971 | Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and in healthy pregnancy |
| Q90681087 | Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort |
| Q28319741 | Low dose methotrexate treatment in adult Still's disease |
| Q57624052 | Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS) |
| Q73003126 | Low-dose pulse cyclophosphamide in the treatment of neuropsychiatric lupus |
| Q37821052 | Lupus and pregnancy: integrating clues from the bench and bedside |
| Q37168021 | Lupus and pregnancy: ten questions and some answers |
| Q67592903 | Lupus comes of age |
| Q34418809 | Lupus pregnancy: is heparin a risk factor for osteoporosis? |
| Q69624918 | Lupus, thrombotic thrombocytopenic purpura, and antiphospholipid antibodies |
| Q77904258 | Lymphocyte activation markers and von Willebrand factor antigen in Wegener's granulomatosis: potential markers for disease activity |
| Q41369454 | Magnetic resonance imaging in Behçet's disease |
| Q58143748 | Major histocompatibility complex associations with primary antiphospholipid syndrome |
| Q72312831 | Malignancy in systemic lupus erythematosus: a report of five cases in a series of 96 patients |
| Q34989343 | Management of antiphospholipid syndrome |
| Q57033429 | Management of antiphospholipid syndrome |
| Q37215921 | Management of hypogammaglobulinaemia occurring in patients with systemic lupus erythematosus |
| Q34354754 | Management of pregnancy in antiphospholipid syndrome |
| Q37874003 | Management of refractory anti-phospholipid syndrome |
| Q71339943 | Management of the Hughes syndrome |
| Q55476101 | Management of the antiphospholipid syndrome. |
| Q35743192 | Management of the obstetric antiphospholipid syndrome |
| Q77550004 | Management of thrombosis and pregnancy loss in the antiphospholipid syndrome |
| Q36242873 | Management of thrombosis in antiphospholipid syndrome and systemic lupus erythematosus in pregnancy |
| Q41197497 | Management of thrombosis in the antiphospholipid syndrome |
| Q44913899 | Managing lupus nephritis in pregnant women: comment on the article by Hahn et al. |
| Q45932712 | Managing lupus patients during pregnancy. |
| Q73724619 | Markers of vascular damage in lupus pregnancy |
| Q36220831 | Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus |
| Q57307370 | McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome |
| Q75828793 | Measuring systemic lupus erythematosus activity during pregnancy: validation of the lupus activity index in pregnancy scale |
| Q58210773 | Migraine and Antiphospholipid Antibodies: No Association Found in Migraine-Discordant Monozygotic Twins |
| Q73822136 | Migraine and stroke in young women |
| Q73447481 | Migraine in Hughes syndrome--heparin as a therapeutic trial? |
| Q77434388 | Minocycline-induced arthritis |
| Q59297895 | Misalignment effects on the load capacity of a hydraulic cylinder |
| Q61895120 | Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment |
| Q28174733 | Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No |
| Q35797933 | Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study |
| Q33357081 | Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients |
| Q33329033 | Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus |
| Q33412915 | Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients |
| Q43519903 | Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients |
| Q72345817 | Mosaic of anti-endothelial antibodies. Review of the first international workshop on anti-endothelial antibodies: clinical and pathological significance Milan, 9 November 1994 |
| Q74151374 | Most anticardiolipin antibodies in mixed connective tissue disease are beta2-glycoprotein independent |
| Q69419198 | Multi-infarct dementia associated with antiphospholipid antibodies. Presentation of 2 cases |
| Q77674623 | Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome |
| Q80862938 | Multiple sclerosis and the antiphospholipid (Hughes) syndrome: a common differential diagnosis? |
| Q69937920 | Multiple small-vessel occlusions in systemic lupus erythematosus |
| Q38753531 | Musculoskeletal manifestations of the antiphospholipid syndrome |
| Q44087206 | Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents |
| Q51784383 | Mycophenolate mofetil treatment in resistant myositis. |
| Q69268727 | Myocardial infarction and antiphospholipid antibodies in SLE and related disorders |
| Q43627481 | N2010 adult-onset Still's disease complicated by hemophagocytic syndrome and catastrophic antiphospholipid syndrome resulting in four limb amputation |
| Q74023947 | Natural immune response involving anti-endothelial cell antibodies in normal and lupus pregnancy |
| Q57330817 | Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study |
| Q37185051 | Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach |
| Q47928982 | Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. |
| Q87416222 | New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies |
| Q47136259 | Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study |
| Q44564840 | Non-infective verrucous endocarditis in a patient with 'primary' antiphospholipid syndrome |
| Q74205342 | Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility |
| Q35189295 | Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies |
| Q34734826 | Nonsteroidal anti-inflammatory drugs and reversible female infertility: is there a link? |
| Q42475036 | Normal expression of tissue factor, thrombomodulin, and annexin V in placentas from women with antiphospholipid syndrome |
| Q34274883 | Novel insights into pathogenesis, diagnosis and treatment of antiphospholipid syndrome |
| Q59297876 | Numerical Study in a Mini Trochoidal-Gear Pump With Multi-Meshing Contact Points |
| Q59297872 | Numerical Study of Impingement Location of Liquid Jet Poured from a Tilting Ladle with Lip Spout |
| Q34056232 | Numerical scoring for the BILAG-2004 index |
| Q37421244 | Numerical scoring for the Classic BILAG index |
| Q40998663 | Obstetric outcome in systemic lupus erythematosus |
| Q64893122 | Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. |
| Q74284472 | Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients |
| Q37215823 | Oxidation of LDL and its clinical implication |
| Q44533319 | Oxidized low-density lipoprotein as a risk factor of thrombosis in antiphospholipid syndrome |
| Q38177964 | Patterns of systemic lupus erythematosus expression in Europe |
| Q79358181 | Periorbital oedema in systemic lupus erythematosus |
| Q92474679 | Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study |
| Q34173981 | Placentation, antiphospholipid syndrome and pregnancy outcome |
| Q73607436 | Plasma tumor necrosis factor alpha levels and the -238*A promoter polymorphism in patients with antiphospholipid syndrome |
| Q67907021 | Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis |
| Q59159766 | Polymorphic light eruption and the HLA DRB1*0301 extended haplotype are independent risk factors for cutaneous lupus erythematosus |
| Q28325364 | Polymyositis complicating D-penicillamine treatment |
| Q38743596 | Polymyositis-dermatomyositis: a clinical review |
| Q38314784 | Possible mechanisms of action of the antiphospholipid binding antibodies |
| Q33382838 | Postpartum spontaneous colonic perforation due to antiphospholipid syndrome |
| Q90832501 | Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index |
| Q101352178 | Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) |
| Q41923591 | Prednisone in lupus nephritis: how much is enough? |
| Q59552743 | Pregnancy Outcomes in Systemic Lupus Erythematosus with and without Previous Nephritis |
| Q37811609 | Pregnancy and reproduction in autoimmune rheumatic diseases |
| Q33578190 | Pregnancy in granulomatous vasculitis |
| Q71829343 | Pregnancy in systemic lupus erythematosus |
| Q43246259 | Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome |
| Q87036962 | Pregnancy outcome in patients with systemic vasculitis: a single-centre matched case-control study |
| Q64039321 | Pregnancy outcomes in mixed connective tissue disease: a multicentre study |
| Q43966888 | Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus |
| Q68584035 | Prevalence & clinical associations of anticardiolipin antibodies in patients with systemic lupus erythematosus in India |
| Q35552242 | Prevalence and associations of an abnormal ankle-brachial index in systemic lupus erythematosus: a pilot study |
| Q40551503 | Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome |
| Q71731245 | Prevalence and clinical significance of subungual splinter haemorrhages in patients with the antiphospholipid syndrome |
| Q42955989 | Prevalence of an abnormal ankle-brachial index in patients with antiphospholipid syndrome with pregnancy loss but without thrombosis: a controlled study |
| Q30978841 | Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data |
| Q85743774 | Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant |
| Q35636529 | Prevalence of the antiphospholipid syndrome in primary systemic vasculitis |
| Q71514165 | Primary antiphospholipid syndrome evolving into systemic lupus erythematosus |
| Q59552940 | Primary antiphospholipid syndrome in pregnancy: an analysis of outcome in a cohort of 33 women treated with a rigorous protocol |
| Q34021321 | Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies |
| Q77910619 | Prolactin, the immune response and lupus |
| Q28196923 | Prophylaxis of the antiphospholipid syndrome: a consensus report |
| Q34087831 | Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus |
| Q81899320 | Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis |
| Q37721600 | Proteomics in antiphospholipid syndrome: a review |
| Q74823604 | Prothrombin mutation is not associated with thrombosis in patients with antiphospholipid syndrome |
| Q72851608 | Psychiatric disorders in patients with systemic lupus erythematosus: lack of association with antiphospholipid antibodies |
| Q58093032 | Psychosis in Systemic Lupus Erythematosus |
| Q43535847 | Pulmonary hypertension in a lupus clinic: experience with twenty-four patients |
| Q71538132 | Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus |
| Q33363443 | Reassessing the status of antiphospholipid syndrome in systemic lupus erythematosus |
| Q56907345 | Recomendaciones sobre el uso de belimumab en el lupus eritematoso sistémico. Guía de Práctica Clínica GEAS-SEMI |
| Q37292999 | Recurrent atraumatic metatarsal, rib and sacral insufficiency fractures in a woman with the antiphospholipid syndrome |
| Q46622469 | Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy |
| Q41413515 | Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus. |
| Q42985798 | Release of calreticulin from neutrophils may alter C1q-mediated immune functions. |
| Q45168730 | Renal artery stenosis in hypertensive patients with antiphospholipid (Hughes) syndrome: outcome following anticoagulation |
| Q35552039 | Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension |
| Q87467570 | Renal involvement in antiphospholipid syndrome |
| Q37637677 | Review: Low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity? |
| Q60699958 | Revised British Isles Lupus Assessment Group 2004 index: A reliable tool for assessment of systemic lupus erythematosus activity |
| Q34553030 | Revisiting antiphospholipid antibodies: from targeting phospholipids to phospholipid binding proteins. |
| Q39216916 | Rheumatological complications of beta-thalassaemia: an overview |
| Q44567276 | Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation |
| Q56907482 | Rituximab and lupus: Good in real life, bad in controlled trials. comment on the article by Lu et al |
| Q37541561 | Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases |
| Q37737138 | Rituximab therapy in lupus nephritis: current clinical evidence |
| Q35925359 | Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. |
| Q45857473 | Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism |
| Q37230504 | Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial |
| Q44355409 | Role of platelet phospholipases in the antiphospholipid antibody syndrome |
| Q47776911 | Role of the Fcgamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis |
| Q37226689 | SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus |
| Q36681749 | Safety and efficacy of fluconazole treatment for Candida oesophagitis in AIDS. |
| Q68093283 | Secondary prevention of esophageal candidiasis with fluconazole in acquired immunodeficiency syndrome |
| Q36307429 | Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study |
| Q61914446 | Series Editor |
| Q24674194 | Seronegative antiphospholipid syndrome |
| Q38090375 | Seronegative antiphospholipid syndrome |
| Q96353745 | Seventy years after Hench's Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus |
| Q36307414 | Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study |
| Q92977632 | Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR) |
| Q37398870 | Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study |
| Q36170981 | Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. |
| Q43782448 | Sneddon syndrome and antiphospholipid antibodies |
| Q69683667 | Sneddon's syndrome |
| Q44233637 | Sneddon's syndrome and primary anti-phospholipid syndrome (PAPS) |
| Q90820946 | Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus |
| Q73016230 | Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome |
| Q72639034 | Specificity of estrogen receptors in rat thymus |
| Q33330250 | Splenectomy for refractory thrombocytopenia in the antiphospholipid syndrome |
| Q43837381 | Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype |
| Q74127765 | Sticky blood and headache |
| Q73469890 | Strain differences in binding properties of estrogen receptors in immature and adult BALB/c and MRL/MP-lpr/lpr mice, a model of systemic lupus erythematosus |
| Q36102500 | Stroke and antiphospholipid syndrome: the treatment debate |
| Q35189292 | Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. |
| Q39095546 | Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients |
| Q74386110 | Syndrome X and Hughes syndrome |
| Q28217439 | Systematic lupus erythematosus and antiphospholipid syndrome during pregnancy |
| Q55933861 | Systemic lupus erythematosus |
| Q73730202 | Systemic lupus erythematosus |
| Q33969870 | Systemic lupus erythematosus and antiphospholipid syndrome during pregnancy: maternal and fetal complications and their management |
| Q80274186 | Systemic lupus erythematosus and pregnancy |
| Q50974131 | Systemic lupus erythematosus flares during pregnancy. |
| Q33356370 | Systemic lupus erythematosus in 50 year olds |
| Q36399103 | Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". |
| Q67833536 | Systemic lupus erythematosus in males: analysis of clinical and laboratory features |
| Q51056997 | Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. |
| Q64051221 | Systemic lupus erythematosus: sex hormones in male patients |
| Q57330769 | Systemic lupus international collaborating clinics renal activity/response exercise: Comparison of agreement in rating renal response |
| Q50647508 | Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. |
| Q57307374 | THU0561 Clinical practice guideline for diagnosis and management of catastrophic antiphospholipid syndrome |
| Q38197445 | Targeted therapy in antiphospholipid syndrome |
| Q45298403 | Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens |
| Q41457485 | Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients |
| Q33416915 | The "primary" antiphospholipid syndrome: major clinical and serological features. |
| Q27469297 | The ANCA test: its clinical relevance |
| Q37190011 | The BILAG-2004 index is sensitive to change for assessment of SLE disease activity |
| Q36331877 | The BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinally |
| Q36252764 | The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients |
| Q37988167 | The DWEYS peptide in systemic lupus erythematosus |
| Q26765038 | The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation |
| Q33385759 | The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe |
| Q84387862 | The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe |
| Q67483553 | The Heart and Antiphospholipid Antibodies in MRL-lpr/lpr Mice |
| Q53322534 | The Sixth International Lupus Conference, Barcelona 24-28 March 2001. |
| Q36884648 | The abdominal manifestations of the antiphospholipid syndrome |
| Q73958812 | The anti-phospholipid antibody syndrome (Hughes syndrome): therapeutic aspects |
| Q28194927 | The antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapy |
| Q72818973 | The antiphospholipid syndrome |
| Q77479829 | The association of pure red cell aplasia with the antiphospholipid syndrome |
| Q36840249 | The central nervous system in systemic lupus erythematosus |
| Q43490656 | The challenge of pregnancy for patients with SLE. |
| Q38040947 | The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review |
| Q38387739 | The clinical spectrum of autoimmune congenital heart block |
| Q85224477 | The clinical value of testing for antibodies to phosphatidylethanolamine (aPE) in patients with systemic lupus erythematosus (SLE) |
| Q42447310 | The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome |
| Q51234694 | The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease. |
| Q38125246 | The current standing of diagnosis of antiphospholipid syndrome associated with systemic lupus erythematosus |
| Q61649304 | The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practice |
| Q54573414 | The effect of OM-89 (Subreum) on the murine model of systemic lupus erythematosus MRL-lpr/lpr. |
| Q86328050 | The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment |
| Q38242432 | The efficacy of novel B cell biologics as the future of SLE treatment: a review |
| Q38221324 | The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review |
| Q37082037 | The frequency and outcome of lupus nephritis: results from an international inception cohort study |
| Q45130401 | The global anti-phospholipid syndrome score in primary APS. |
| Q33379294 | The hematologic manifestations of the antiphospholipid syndrome |
| Q68033854 | The hepatic complications of the antiphospholipid antibodies |
| Q40474976 | The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. |
| Q44221268 | The importance of antiphospholipid antibodies. |
| Q72619159 | The management of thrombosis in the antiphospholipid-antibody syndrome |
| Q41072113 | The mosaic of SLE-II: highlights of the fourth international conference on systemic lupus erythematosus--March 1995. |
| Q80349512 | The placental bed in pregnancies complicated by primary antiphospholipid syndrome |
| Q40237986 | The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients |
| Q33420116 | The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features |
| Q37170754 | The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus |
| Q33501859 | The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. |
| Q54566898 | The systemic lupus erythematosus (SLE) disease autoantigen-calreticulin can inhibit C1q association with immune complexes. |
| Q37027973 | The treatment of antiphospholipid syndrome: a harmonic contrast |
| Q33796222 | The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients |
| Q41930631 | The use of hydroxychloroquine in lupus pregnancy: the British experience. |
| Q84238807 | The use of laboratory methods in differential diagnosis and treatment of SLE and antiphospholipid syndrome |
| Q33340382 | The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. |
| Q77329132 | Therapeutic advances in systemic lupus erythematosus |
| Q34074960 | Therapy of systemic lupus erythematosus: new agents and new evidence |
| Q39404443 | Thin-layer chromatography immunostaining in detecting anti-phospholipid antibodies in seronegative anti-phospholipid syndrome |
| Q73306638 | Thrombocytopenia in the antiphospholipid syndrome |
| Q59552997 | Thromboprophylaxis in antiphospholipid syndrome pregnancies with previous cerebral arterial thrombotic events: is warfarin preferable? |
| Q51553407 | Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. |
| Q44653622 | Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event |
| Q72702847 | Thrombosis and antiphospholipid syndrome: a preliminary assessment of three antithrombotic treatments |
| Q71843676 | Thrombosis in Churg-Strauss syndrome. Beyond vasculitis? |
| Q33499291 | Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression |
| Q88153708 | Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort |
| Q67569384 | Thymulin and its role in immunomodulation |
| Q42512344 | Thymulin modulates cytokine release by peripheral blood mononuclear cells: a comparison between healthy volunteers and patients with systemic lupus erythematosus |
| Q73350589 | Tissue factor in antiphospholipid syndrome: shifting the focus from coagulation to endothelium |
| Q34502449 | Towards a better understanding of the clinical association of anti-DFS70 autoantibodies |
| Q72011194 | Transverse myelitis as a first manifestation of systemic lupus erythematosus: a case report |
| Q44754455 | Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies |
| Q56907388 | Tratamiento depletivo de células B en enfermedades autoinmunitarias sistémicas. Recomendaciones de uso en la práctica clínica |
| Q45065231 | Treatment of esophageal candidiasis with fluconazole in acquired immunodeficiency syndrome. Comparative study of 2 therapeutic schemes |
| Q43342883 | Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). |
| Q42955530 | Treatment of mesenteric angina with prolonged anticoagulation in a patient with antiphospholipid (Hughes) syndrome and coeliac artery stenosis |
| Q28196667 | Treatment of pregnancy loss in Hughes syndrome: a critical update |
| Q28196925 | Treatment of pregnant patients with antiphospholipid syndrome |
| Q74022703 | Treatment of systemic lupus erythematosus |
| Q41925924 | Treatment of systemic lupus erythematosus: myths, certainties and doubts |
| Q77365482 | Treatment of the antiphospholipid syndrome in pregnancy |
| Q56907356 | Trial of SLE therapies in real-world settings |
| Q73069588 | Up-regulated tissue factor expression in antiphospholipid syndrome |
| Q37373055 | Update on immunotherapy for systemic lupus erythematosus--what's hot and what's not! |
| Q34227018 | Update on therapy--thalidomide in the treatment of lupus |
| Q91502625 | Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen |
| Q53654665 | Validation of a commercially available kit to detect anti-phosphatidylserine/prothrombin antibodies in a cohort of systemic lupus erythematosus patients. |
| Q35552725 | Value of IgA anticardiolipin and anti-beta2-glycoprotein I antibody testing in patients with pregnancy morbidity |
| Q80249563 | Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome |
| Q37324878 | Vasculitis induced by tumor necrosis factor-targeted therapies |
| Q35189289 | Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis |
| Q42969030 | Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome |
| Q54231629 | Warfarin and azathioprine: a drug interaction does exist. |
| Q74105355 | Warfarin for multiple sclerosis? |
| Q34226222 | Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus |
| Q84331770 | [Adaptation and validation of the Spanish version of a disease-specific quality of life measure in patients with systemic lupus erythematosus: the Lupus quality of life] |
| Q58001014 | [Anti-phospholipid antibodies] |
| Q70268361 | [Antiendothelial cell antibodies] |
| Q85273216 | [Antiphospholipid syndrome in obstetrics] |
| Q69456981 | [Avascular necrosis of the bone and systemic lupus erythematosus] |
| Q95809611 | [Belimumab in systemic lupus erythematosus: a guide for its use in the daily practice] |
| Q68222475 | [Determination of beta-2-microglobulin levels in patients with systemic lupus erythematosus: correlation with clinical and biological parameters] |
| Q87430397 | [Diagnosis of antiphospholipid syndrome: From an historical perspective to the emergence of new autoantibodies] |
| Q77589666 | [Hughes syndrome and thrombosis: the debate goes on] |
| Q72598954 | [Hughes syndrome: anticardiolipin or antiphospholipid] |
| Q81715863 | [Neurological manifestations of the antiphospholipid syndrome] |
| Q89365172 | [Pregnancy in systemic autoimmune diseases: Myths, certainties and doubts] |
| Q77920084 | [Systemic autoimmune diseases during pregnancy: a practical approach] |
| Q44123922 | [Thrombocytopenia in the antiphospholipid syndrome] |
| Q69235920 | [Thrombocytopenia, pregnancy and systemic lupus erythematosus] |
| Q69669017 | [Trichomegaly: an exceptional expression of the acquired immunodeficiency syndrome] |
| Q72767523 | beta 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome |
Search more.